|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_ocn947837616 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
151207s2016 nyua ob 001 0 eng |
| 010 |
|
|
|a 2020677145
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d N$T
|d YDXCP
|d OCLCF
|d EBLCP
|d YDX
|d AGLDB
|d SNK
|d DKU
|d AUW
|d MHW
|d IGB
|d D6H
|d VTS
|d G3B
|d S8J
|d S9I
|d STF
|d M8D
|d DAC
|d OCLCO
|d OCLCA
|d OCLCO
|d OCLCQ
|
| 019 |
|
|
|a 959031292
|
| 020 |
|
|
|z 9781634844185
|q (ebook)
|
| 020 |
|
|
|a 1634844033
|q (hbk)
|
| 020 |
|
|
|a 9781634844031
|q (hbk)
|
| 020 |
|
|
|a 1634844181
|q electronic bk
|
| 020 |
|
|
|a 9781634844185
|q electronic bk
|
| 029 |
1 |
|
|a AU@
|b 000062420161
|
| 035 |
|
|
|a (OCoLC)947837616
|z (OCoLC)959031292
|
| 050 |
0 |
0 |
|a RM333.5
|
| 060 |
|
4 |
|a QV 77.9
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
0 |
|a 615.7/882
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Antipsychotic drugs :
|b classification, pharmacology and long-term health effects /
|c Mark L. Aguilar, editor.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical,
|c [2016]
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Psychiatry- theory, applications, and treatments
|
| 500 |
|
|
|a "Nova biomedical."
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
|
|
|a Description based on print version record and CIP data provided by publisher.
|
| 505 |
0 |
|
|a ANTIPSYCHOTIC DRUGS CLASSIFICATION, PHARMACOLOGY AND LONG-TERM HEALTH EFFECTS ; ANTIPSYCHOTIC DRUGS CLASSIFICATION, PHARMACOLOGY AND LONG-TERM HEALTH EFFECTS ; CONTENTS ; PREFACE ; Chapter 1 LONG-ACTING ANTIPSYCHOTICS: THE FACTS AND THE MYTHS FROM SYMPTOMS MANAGEMENT TO TARGETED TREATMENT ; ABSTRACT ; INTRODUCTION ; 1. ADHERENCE TO TREATMENT IN MENTAL DISORDERS: DEFINITIONS, BOUNDARIES AND MISCONCEPTIONS ; 1.1. From Compliance to Adherence to Treatment ; 1.2. The Factors Affecting Adherence to Treatments in Somatic Diseases
|
| 505 |
8 |
|
|a 1.3. Adherence to Treatment in Mental Disorders: From Low Insight to Recovery 2. HISTORICAL BACKGROUND ; 2.1. The Development of Long-Acting Antipsychotics in the 1960s Psychiatric Cultural Context ; 2.2. The Question of Polypharmacy vs. Monotherapy ; 2.3. An Overview of the Development of First Generation LAIs ; 3. LONG-ACTING FGAS: HISTORY, DEVELOPMENT AND PHARMACEUTICAL PROPERTIES ; 3.1. Fluphenazine Enanthate/Decanoate ; 3.2. Clopenthixol Enanthate and Zuclopenthixol Decanoate/Acetate ; 3.3. Flupenthixol Decanoate ; 3.4. Haloperidol/Bromperidol Decanoate
|
| 505 |
8 |
|
|a 3.5. Pipothiazine Palmitate/Undecylenate 3.6. Fluspirilene/Penfluridol ; 3.7. Perphenazine Enanthate/Decanoate ; 3.8. Oxyprothepin Decanoate, the LAI that came in from the Cold; 4. THE CHALLENGE OF THE 'LAST RESORT' TREATMENTS: NEW TECHNOLOGIES FOR THE SECOND GENERATION LAIS ; 4.1. Risperidone Long-Acting Injection ; 4.3. Paliperidone Palmitate ; 4.4. Olanzapine Pamoate ; 4.5. Aripiprazole, Long-Acting Injectable Formulation ; 5. THE UTILIZATION OF LAIS: CLINICAL PRINCIPLES OF BEST TREATMENT PRACTICE
|
| 505 |
8 |
|
|a 5.1. Support in the Community is Necessary to Tackle Non-Adherence to Treatments when Using LAIs 5.2. Practicioners' and Patients' Attitudes towards LAIs ; 5.3. The Treatment with LAIs might be Effectively Supported by Treatment Alliance and Effective Communication Strategies ; 5.4. More Benefits than Risks from the Treatment with Long-Acting Antipsychotics? ; 6. RESEARCH INDICATIONS ON LAIS: BEST EVIDENCE FROM REAL-WORLD PRACTICE ; 6.1. Introduction ; 6.2. Materials and Methods ; 6.2.1. The Catchment Area ; 6.2.2. Assessment of LAIs use in Portogruaro CMHC
|
| 505 |
8 |
|
|a 6.2.3. Characteristics of the Sample 6.3. Results ; 6.4. Discussion and Conclusion ; 7. THE NEW EVIDENCE STEMMING FROM RESEARCH ; 7.1. Forthcoming Antipsychotic Injections and other Long-Acting Formulations for Integrated Mental Health Treatments ; 7.1.1. Iloperidone Long-Acting Injection ; 7.1.2. Transdermal Olanzapine Patches ; 7.1.3. Transdermal Risperidone Patches ; 7.1.4. Aripiprazole Long-Acting Oral Formulation ; 7.1.5. Paliperidone Three-Month Long-Acting Injection ; 7.2. Long-Acting Drugs for New or Unusual Context ; 7.2.1. LAIs and First-Episode Psychoses
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Antipsychotic drugs.
|
| 650 |
|
2 |
|a Antipsychotic Agents
|
| 650 |
|
6 |
|a Neuroleptiques.
|
| 650 |
|
7 |
|a MEDICAL / Pharmacology
|2 bisacsh
|
| 650 |
|
7 |
|a Antipsychotic drugs.
|2 fast
|0 (OCoLC)fst00810669
|
| 700 |
1 |
|
|a Aguilar, Mark L.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Antipsychotic drugs
|d New York : Nova Biomedical, [2016]
|z 9781634844031 (hbk)
|w (DLC) 2015959369
|
| 830 |
|
0 |
|a Psychiatry- theory, applications, and treatments series.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1226252
|z Texto completo
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 12759195
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1226252
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4586592
|
| 994 |
|
|
|a 92
|b IZTAP
|
